Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 344

1.

Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma.

Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu WJ, Homsi J, Davies M, McIntyre S, Hwu P.

Am J Clin Oncol. 2011 Dec;34(6):603-10. doi: 10.1097/COC.0b013e3181f9456a.

PMID:
21150567
2.

Contemporary surgical treatment of advanced-stage melanoma.

Essner R, Lee JH, Wanek LA, Itakura H, Morton DL.

Arch Surg. 2004 Sep;139(9):961-6; discussion 966-7.

PMID:
15381613
3.

Prognostic factors in 1,521 melanoma patients with distant metastases.

Barth A, Wanek LA, Morton DL.

J Am Coll Surg. 1995 Sep;181(3):193-201.

PMID:
7670677
4.

Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience.

Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, Urban A, Schell H, Hohenberger W, Sauer R.

Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):607-18.

PMID:
10348291
5.

A single-institution validation of the AJCC staging system for stage IV melanoma.

Neuman HB, Patel A, Ishill N, Hanlon C, Brady MS, Halpern AC, Houghton A, Coit DG.

Ann Surg Oncol. 2008 Jul;15(7):2034-41. doi: 10.1245/s10434-008-9915-0. Epub 2008 May 9.

PMID:
18465172
6.

Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma.

Murali R, Haydu LE, Long GV, Quinn MJ, Saw RP, Shannon K, Spillane AJ, Stretch JR, Kefford RF, Thompson JF, Scolyer RA.

Ann Surg Oncol. 2012 Jun;19(6):1782-9. doi: 10.1245/s10434-012-2265-y. Epub 2012 Feb 14.

PMID:
22350600
7.

Stage-IV melanoma and pulmonary metastases: factors predictive of survival.

Neuman HB, Patel A, Hanlon C, Wolchok JD, Houghton AN, Coit DG.

Ann Surg Oncol. 2007 Oct;14(10):2847-53. Epub 2007 Aug 7.

PMID:
17680317
8.

A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods.

Balch CM, Murad TM, Soong SJ, Ingalls AL, Halpern NB, Maddox WA.

Ann Surg. 1978 Dec;188(6):732-42.

9.

Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.

Owen SA, Sanders LL, Edwards LJ, Seigler HF, Tyler DS, Grichnik JM.

Cancer. 2001 Mar 1;91(5):983-91.

PMID:
11251950
10.

[Locally recurrent and metastatic malignant melanoma. Long-term results and prognostic factors after percutaneous radiotherapy].

Seegenschmiedt MH, Keilholz L, Pieritz A, Altendorf-Hofmann A, Urban A, Schell H, Hohenberger W, Sauer R.

Strahlenther Onkol. 1999 Sep;175(9):450-7. German.

PMID:
10518979
11.

Increased incidence of brain metastases in cutaneous head and neck melanoma.

Daryanani D, Plukker JT, de Jong MA, Haaxma-Reiche H, Nap R, Kuiper H, Hoekstra HJ.

Melanoma Res. 2005 Apr;15(2):119-24.

PMID:
15846145
12.

Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy.

Weide B, Richter S, B├╝ttner P, Leiter U, Forschner A, Bauer J, Held L, Eigentler TK, Meier F, Garbe C.

PLoS One. 2013 Nov 28;8(11):e81624. doi: 10.1371/journal.pone.0081624. eCollection 2013.

13.

Malignant melanoma in Turkey: a single institution's experience on 475 cases.

Tas F, Kurul S, Camlica H, Topuz E.

Jpn J Clin Oncol. 2006 Dec;36(12):794-9. Epub 2006 Oct 23.

PMID:
17060409
14.

Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.

Minor DR, Moore D, Kim C, Kashani-Sabet M, Venna SS, Wang W, Boasberg P, O'Day S.

Oncologist. 2009 Oct;14(10):995-1002. doi: 10.1634/theoncologist.2009-0083. Epub 2009 Sep 23.

16.

Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute.

Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, Sober AJ, Haluska FG.

Melanoma Res. 2005 Feb;15(1):77-82. Review.

PMID:
15714125
17.

Postoperative radiotherapy for primary mucosal melanoma of the head and neck.

Temam S, Mamelle G, Marandas P, Wibault P, Avril MF, Janot F, Julieron M, Schwaab G, Luboinski B.

Cancer. 2005 Jan 15;103(2):313-9.

18.

Gene expression profiling of primary cutaneous melanoma and clinical outcome.

Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A; Melanoma Group of the European Organization for Research and Treatment of Cancer.

J Natl Cancer Inst. 2006 Apr 5;98(7):472-82.

PMID:
16595783
19.

Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.

Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U; American Joint Committee on Cancer Stage IV Melanoma; EORTC 18951.

J Clin Oncol. 2007 Apr 20;25(12):1562-9.

PMID:
17443000
20.

Disease progression in patients with thin cutaneous melanomas (tumour thickness < or = 0.75 mm): clinical and epidemiological data from the Tumour Center Munich 1977-98.

Schmid-Wendtner MH, Baumert J, Eberle J, Plewig G, Volkenandt M, Sander CA.

Br J Dermatol. 2003 Oct;149(4):788-93.

PMID:
14616371

Supplemental Content

Support Center